603590
vs
S
Shanghai Composite
603590
Over the past 12 months, Beijing Konruns Pharmaceutical Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +83% compared to the Shanghai Composite's +25% growth.
Stocks Performance
603590 vs Shanghai Composite
Performance Gap
603590 vs Shanghai Composite
Performance By Year
603590 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Beijing Konruns Pharmaceutical Co Ltd
Glance View
Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. The company is headquartered in Beijing, Beijing and currently employs 473 full-time employees. The company went IPO on 2018-08-27. The firm's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Company’s present products under research include a range of innovative and generic drugs for tumors and blood. The firm mainly distributes its products in the domestic market.